# Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

> **NCT06907511** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 720 (actual)

## Conditions studied

- Pandemic Influenza Immunization
- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** Pandemic flu H5 HA mRNA SD2 vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06907511
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-17
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 720 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06907511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06907511, "Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06907511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*